Suchergebnisse - "Van Marrewijk, Corine"

PubPharm (5)

1

Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

enthalten in: Journal of Crohn's & colitis | 2019

von Sluiter, R. | Van Marrewijk, C. | De Jong, D. | +11

2

Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases

enthalten in: European journal of gastroenterology & hepatology | 2018

von Broekman, M. | Coenen, M. | Wanten, G. | +11

3

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing

enthalten in: Inflammatory bowel diseases | 2017

von Broekman, M. | Coenen, M. | van Marrewijk, C. | +10

4

Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease

enthalten in: Journal of Crohn's & colitis | 2017

von Wong, D. | Coenen, M. | Vermeulen, S. | +11

5

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

enthalten in: Gastroenterology | 2015

von Coenen, M. | de Jong, D. | van Marrewijk, C. | +113

CommentIn: Gastroenterology. 2015 Oct;149(4):850-3. - PMID 26311276

1
[1]